Chapter 19b Blood, cont d

Similar documents
Overview of Anatomy and Physioloy II Second Year Students

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.

The Story of the Platelet Clump. Wayne Hall MTN Network Laboratory Magee-Womens Research Institute Pittsburgh, PA

BLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury.

1 Adequate. Some key words were used and used correctly. Some errors were made in the use of key words.

Coagulation in perspective: Blood management. Objectives

Dr. Suzana Voiculescu

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis

VIII. Validation Evaluation Comparative Chart Application Fields of PRP Advantages of MiroPRP for skin treatments MicroPRP and Mico-Mesotherapy

At the conclusion of this lesson you should be able to:

Rheological and biochemical analyses on blood coagulation ~ Discovery of a new pathway under stagnant flow conditions ~

Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:

Common Inherited Bleeding Disorders

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014

De l'utilisation de la microscopie intravitale pour étudier la thrombose in vivo et tester de nouveaux médicaments antithrombotiques- 1er partie

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

Adrenal Gland. MEDULLA Epinephrine CORTEX. Zona reticularis --adrenal androgen. Zona fasciculata --glucocorticoids

Immunoglobulins. Biological Properties

Sergeant System s Immune System Defense Team Webquest

Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Basic Antibody Structure. Multiple myeloma = cancerous plasma cells Monomer = 150,000. Chapter 4. Immunoglobulin Structure and Function

COAGULATION: BASIC PRINCIPLES. Peyman Eshghi Prof. of Pediatric Hematology & Oncology

Blood Product Utilization

BACTERIA. NO or membrane bound WHAT ARE THE TWO TYPES OF PROKARYOTES? TYPES EUBACTERIA ARCHAEBACTERIA. bilayer embedded with

Phylogenetic Assessment of Innate Immunity s Complement Component C3 and Factor B (Bf)

Upon completion of the Clinical Hematology rotation, the MLS student will be able to:

Laboratory Manual Selected Experiments in General Physiology, Basics of Hematology & Nerve-Muscle Physiology

Rheological Properties of Fibrin Clots

ROTEM Basic Interpretation Guide

RegenACR. autologous cellular regeneration. RegenACR A-PRP treatment. collagen fibers. 1,2 texture and elasticity. 3 volume & strength.

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma

Arthrex Angel TM System. Indication-specific PRP and PRF gel preparations

From Stem Cell to Any Cell

Immunotherapy in myeloma

LEARN. about. Please see Important Safety Information on pages 3-5 and enclosed full Prescribing Information.

CHAPTER 5 COMPLEMENT

Immunology: Antibody Basics

Our detailed aims were:

Hematopoietic Stem Cells

Basic coagulation applications and case studies

XN Hematology Case Studies Every Picture Tells a Story

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications

Higher Human Biology Unit 1: Human Cells Pupils Learning Outcomes

DNA Technology. B. Using Bacteria to Clone Genes: Overview:

Myeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation

Biological evaluation of medical devices. Part 4: Selection of tests for interactions with blood

Platelet transfusion therapy. Orieji Illoh, M.D. January 23, 2007

SEED Coagulation. Sysmex Educational Enhancement and Development April 2014

Residual Serum Thrombin

IMMUNOBIOLOGY : AN INTRODUCTION

Marcia L. Zucker, Ph.D. ZIVD LLC

American Association of Immunology Heidi Anderson: Lesson Plan for Cell Signaling and Immune System

PV92 PCR Bio Informatics

Guidelines for the use of blood warming devices(aabb) Reference: 2002 AABB

Marcia L. Zucker, Ph.D. ZIVD LLC

Fibrin Glue Based Clotting Factor Cocktail for High Throughput in vitro. Thrombogenicity Screening. Yvette Michelle Beben

FORENSIC SEROLOGY. Chapter PRENTICE HALL 2008 Pearson Education, Inc. Upper Saddle River, NJ 07458

OVERVIEW OF LABORATORY DIAGNOSTIC TESTING FOR PLATELET DISORDERS

The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors

The clinical utility of IPF in thrombocytopenia

Section 8. To introduce the basic theory and principles of collecting blood for Intraoperative Cell Salvage (ICS)

Hematopoietic Stem Cells

Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. JournalClub Emilie Hrdliczka

Category Storage Shelf Life Additional Criteria

MISSION - Set (align) the arm bone, then apply the blue cast. The cast needs to be all the way down, and it needs to completely cover the break.

Anticlotting mechanisms 1: physiology and pathology

A Level. A Level Biology. Cells, Microscopes, Cell Cycle and Immunity Questions. AQA, OCR, Edexcel. Name: Total Marks: Page 1

OERMATAN SULFATE: A NEW CONCEPT IN ANTITHROMBOTIC THERAPY

XS-1000i New Sysmex 5-part diff haematology analyser with fluorescence technology

No-wash, no-lyse detection of phagocytic cells via a phrodo BioParticles functional assay in human whole blood on the

Appendix B. Glossary of Acronyms and Terms

Chapter 3 Nucleic Acids, Proteins, and Enzymes

"Release of growth factors in PRP activated with thrombin."

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm

2 Thomas G. DeLoughery

Sepsis-Associated Disseminated Intravascular Coagulation Thromboembolic Disease

Bioreactors in tissue engineering

Apheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017

Nucleic Acids, Proteins, and Enzymes

Immunology, Microbiology and Biotechnology

Adipose rabbit mesenchymal stem cells for the treatment of the chronic scar tissue of the vocal cords

The Hollow Fiber Bioreactor and Cell Co-Cultivation

2 Gene Technologies in Our Lives

STRUCTURE-FUNCTION RELATIONSHIPS OF INTERSTITIAL TRANSPORT AND MECHANICS IN BLOOD CLOTS

Interaction of blood cells with the vessel wall in thrombosis

Neutrophil support for patients with cancer receiving myelosuppressive chemotherapy

Transcription:

Chapter 19b Blood, cont d White Blood Cells WBCs account for less than 1% of blood volume. There are two major histological categories of WBCs the granulocytes and the agranulocytes. GRANULOCYTES are Basophils, Eosinophils and Neutrophils (BEN) o Basophils account for less than 1% of the WBCs, and they take up basic due you see mostly the granules on the histology slide. Basophils release HISTAMINE, so they are part of the allergy response. Basophils circulate around, and their buddies, the Mast Cells are in tissues. An example of a Mast Cell is a Langerhans cell. o Eosinophils account for 2-4% of WBCs and they take up acidic dye (granules show up red.) They have a bi-lobed nucleus that pretty much looks like two nuclei, or an alien face. These cells are phagocytic, but don t kill their prey by phagocytosis. They use phagocytosis to clear up cellular debris, but for dealing with pathogens they attack it as a group and release their deadly enzymes. Eosinophils are high in response to PARASITE INFECTION! o Neutrophils account for the majority of WBCs 50-70%. They do not take up dyes! They are going to be present when you have a BACTERIAL INFECTION. Though they are smaller than the macrophages, there are so many of them that they can get the job done. They are also phagocytic, and they contain lysosomal enzymes as well as bactericides. AGRANULOCYTES are Lymphocytes and Monocytes o Lymphocytes are rather small compared to other leukocytes, but they have a huge round nucleus and you can t see much of the cytoplasm. They mostly live in lymphatic tissues, and there are three types: o B-Lymphocytes (B-cells) o T-Lymphocytes (T-cells) Specific immune response o NK Cells (macrophages) Nonspecific immune response o Monocytes have a large heart-shaped nucleus. These cells circulate temporarily but eventually enter tissues as MACROPHAGES. They are phagocytic! Specific and non-specific (general) immunity General immunity: Granulocytes (Basophils, Neutrophils and Acidophils) Monocytes An example of general immunity is inflammation. It occurs the same way for every injury, no matter where it is or how severe it is. The secretion of histamine causes inflammation the basophils and mast cells secrete histamine! Specific immunity: T-lymphocytes (cell-mediated immunity) B-lymphocytes (humoral immunity)

The T-cells are involved in cell-mediated immunity, meaning they get involved in handto-hand combat with the pathogens. They come directly into contact with the invading cells and destroy them! The B-cells are involved in humoral immunity, which means they secrete antibodies (immunoglobulins) to do the dirty work for them. The antibodies then attack! Unique characteristics of WBCs (leukocytes) o WBCs are true cells. They have a nucleus and can divide/repair o Most WBCs are phagocytic o Large populations of WBCs are found in CT proper and lymphatic tissues o They are the only blood cells that can leave circulation and enter tissues through a process called diapedesis o They are called to action via chemotaxis attraction to specific chemical stimuli Production of WBCs All blood cells start with the stem cell which is the HEMOCYTOBLAST. It then branches to the two less-specialized stem cells the MYELOID stem cell produces the granulocytes and the monocytes. The LYMPHOID stem cell produces lymphocytes. The committed cell for each cell type is: MYELOBLAST produces eosinophils MYELOBLAST produces neutrophils MYELOBLAST produces basophils MONOBLAST produces monocytes LYMPHOBLAST produces lymphocytes Chemical messengers known as CSF (colony stimulating factors) tell the developing cells what kind of cell to specify. o EPO tells the progenitor cell to make erythroblasts. o EPO tells the blast cell to make erythroblasts o GMCSF tells the progenitor cell to make granulocytes and monocytes o GCSF tells the blast cell to make granulocytes o MCSF tells the blast cell to make monocytes So, the pathway for the production of blood cells for each of the cell types is as follows: Pluripotent Stem Cell Committed Produces Process Stem Cell Cell Hemocytoblast Myeloid S.C. Proerythroblast Erythrocyte Erythropoiesis Hemocytoblast Myeloid S.C. Myeloblast Basophil Leukopoiesis Hemocytoblast Myeloid S.C. Myeloblast Eisonophil Leukopoiesis Hemocytoblast Myeloid S.C. Myeloblast Neutrophil Leukopoiesis Hemocytoblast Myeloid S. C. Monoblast Monocyte Leukopoiesis Hemocytoblast Lymphoid S.C. Lymphoblast Lymphocyte Leukopoiesis Hemocytoblast Myeloid S.C. Megakaryoblast Platelet Thrombocytopoiesis

We can also make a synthetic GCSF (filgrastin or Neupogen). It is used by cancer patients to help them develop more neutrophils to support the immune system during chemotherapy. Recall that neutrophils are the major phagocyte in circulation. WBC disorders: o Leukopenia = not enough WBCs (results from chemotherapy) o Leukocytosis = too many WBCs can be because you are fighting an infection, or because of cancer causing the abnormal production of WBCs. Production of Platelets (thrombocytopoiesis) The production of platelets begins with the HEMOCYTOBLAST, and the committed cell is the MEGAKARYOBLAST. It then becomes a PROMEGAKARYOCYTES, but this is not a platelet yet! Next, it is a MEGAKARYOCYTE, which breaks off into pieces to become about 4,000 platelets. Platelets are little pieces of cells! These little pieces squeeze through capillary wall in the bone marrow to go out into circulation. The granules of platelets are chemical messengers and enzymes that are involved in hemostasis they create a plug until the tissue is fully repaired. They do this by facilitating clot formation and converting fibrinogen to fibrin. The chemical messenger for this pathway is thrombopoietin (TPO) TPO stimulates the development of platelets. Hemostasis Hemostasis is the process of stopping bleeding! It consists of three general phases: 1. Vasoconstriction just upstream from the break. This is an immediate response that lasts about 30 minutes. Smooth muscles cells have a vascular spasm when they are damaged this is another way of saying they undergo vasoconstriction. This constriction buys us time while we complete phase 2. Besides slowing the flow of blood, a few other things happen at this time: a. The endothelial cells release their chemical messenger (endothelin) that reinforce the smooth muscle spasm and cause a proliferation of cells and fibers for tissue repair. b. The endothelial cell membrane becomes sticky, which helps platelets plugs adhere to the injury site c. The basal lamina is exposed to blood flow 2. Platelet plug formation takes about 1 minute, but also starts immediately. In this stage the platelets adhere to the site of injury on exposed collagen fibers + basal lamina + sticky endothelial cells. This process is called platelet aggregation and it creates a platelet plug. Though not a great seal (it still needs the fibrin mesh), the platelets release: a. Ca ++ which promotes aggregation in a positive feedback loop b. Seratonin which enhances vasoconstriction of the vessel c. ADP which enhances aggregation and secretion, attracting more platelets. Also a positive feedback loop d. Clotting factors, which enhance vessel repair e. PDGF (platelet derived growth factor) that enhances vessel repair

f. Thromboxane A 2, which stimulates aggregation and secretion as well as secretion it is inhibited by aspirin (aspirin is an antiprostaglandin). This plug formation is regulated locally by prostacyclin from the endothelial cells, which work as a negative feedback loop to prevent the clot from getting too big and encroaching on non-injured tissues. 3. Coagulation is a delayed response delayed by about 30 seconds and takes about 5 minutes to complete. The reason it takes so long is that there are about 30 different clotting factors that all work in a complicated pathway to convert fibrinogen to fibrin. There are two components to the process the extrinsic pathway (stimulated by trigger outside the blood) and the intrinsic pathway (stimulated by trigger in the blood), and they converge at Clotting Factor 10. From there, prothrombinase converts prothombin to thrombin, and thrombin converts fibrinogin to fibrin. The final product in the coagulation phase is the fibrin mesh. Procoagulants are things that promote clot formation. These factors include Ca 2+ and various plasma proteins called proenzymes these are activated in the chain reaction. Anticoagulants are things that inhibit clot formation. These provide control in the form of negative feedback. Examples are heparin (from basophils and mast cells), Thrombomodulin (from endothelial cells) and Prosacyclin. The EXTRINSIC PATHWAY is faster and originates from the vessel wall. The INTRINSIC PATHWAY is not as fast, but is more robust. Though clotting can be initiated by either one, they usually work together and converge at a common pathway. The end result of both of them working together is that once prothombinase is produced, then clotting happens very fast in about 10-15 seconds. The prothombinase pathway is: Prothombinase stimulates the synthesis of prothrombin which leads to thrombin, which leads to fibrinogen becoming fibrin, which creates the fibrin mesh! Recall that Vitamin-K is needed for the synthesis of prothrombin, and that fibrinogen is the dissolved plasma protein. Post Hemostasis is clot retraction and repair this happens within 30-60 minutes. In this stage 1. Contractile proteins within the platelets contract, which pulls the vessel edges closer together this is called clot retraction. 2. Endothelium and smooth muscle regenerate and repair. This is stimulated in part by platelet-derived growth factor (PDGF), which is one of the chemical messengers from the platelet granules 3. Once healed, fibrinolysis removes the temporary clot. This is mediated by the enzyme plasmin.

Disorders of Hemostasis There are two major types of disorders of hemostasis thromboembolytic disorders and bleeding disorders. Thromboembolytic disorders have to do with inappropriate clot formation. When an abnormal clot forms on a vessel wall this is called a THROMBUS. If it breaks off and floats downstream it is called an EMBOLUS. When it lodges and blocks the blood flow causing all kinds of damage, this is called an EMBOLISM. Embolisms cause strokes and heart attacks. Bleeding disorders have to do with abnormal bleeding due to the inability to form clots. o Thrombocytopenia is a platelet deficiency. This is caused by damaged bone marrow which can t function properly. o Insufficient procoagulants can also affect one s ability to make clots. This happens with liver disease/dysfunction and Vit-K deficiency. Recall that the liver produces most of the blood proteins, including fibrinogen. No fibrinogen is a very bad situation to be in. o Hemophilias are genetic bleeding disorders that have similar signs and symptoms of the ones listed above. The individual is missing a clotting factor (it only takes one missing factor to screw up the pathway). Sometimes this factor can be given exogenously, or the person has to get frequent plasma/whole blood transfusions.

Marieb, E. N. (2006). Essentials of human anatomy & physiology (8th ed.). San Francisco: Pearson/Benjamin Cummings. Martini, F., & Ober, W. C. (2006). Fundamentals of anatomy & physiology (7th ed.). San Francisco, CA: Pearson Benjamin Cummings.